Amino 4-(aminomethyl)cyclohexane-1-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Amino 4-(aminomethyl)cyclohexane-1-carboxylate
• 英文别名: amino 4-(aminomethyl)cyclohexane-1-carboxylate
• 化学式: C₈H₁₆N₂O₂
• 分子量: 172.22
• InChiKey: PYTBXPGXIAYYMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  78.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF<br/>[FR] TRIOXACARCINES, CONJUGUÉS TRIOXACARCINE-ANTICORPS, ET LEURS UTILISATIONS
  申请人：HARVARD COLLEGE

  公开号：WO2014082065A1

  公开（公告）日：2014-05-30

  Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group - L1 -(A-L2 )a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.

  本文提供的是Formula（A）的三氧卡西青霉素-抗体药物偶联物及其药学上可接受的盐，其中至少包括一个-L1-（A-L2）a-B的组合，其中a是1到10之间的整数，L1不存在或是一个连接基团，A是由两个互补基团（X和Y）反应形成的基团，L2不存在或是另一个连接基团，B是抗体或抗体片段。还提供了制备这些抗体药物偶联物的方法，其药学上可接受的组成物，以及其使用和治疗的方法。此外，还提供了三氧卡西青霉素-抗体药物偶联物的前体，未与抗体偶联的新型三氧卡西青霉素，其药学上可接受的组成物，以及其使用和治疗的方法。
• [EN] CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF<br/>[FR] PEPTIDES CYTOTOXIQUES ET LEURS CONJUGUÉS
  申请人：IRM LLC

  公开号：WO2015095301A2

  公开（公告）日：2015-06-25

  Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: Formula (I) and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.